The Nomination Committee's proposal for the election of Board members and Chairperson of the Board in BioArctic AB
Rhea-AI Summary
BioArctic (Nasdaq: B) announces the Nomination Committee's proposals for the Annual General Meeting on May 28, 2026. The committee proposes an eight-member board, re-electing Eugen Steiner as chair and six existing members, and adding Philip Scheltens and Linda Nilsson as new board members.
Pär Gellerfors has declined re-election; Linda Nilsson is proposed to represent the Gellerfors family's holding company. The Nomination Committee members represent ~57% of shares and ~83% of votes.
Positive
- Board expanded to 8 members, supporting governance continuity
- Eugen Steiner re-elected as chair, preserving leadership stability
- Philip Scheltens added: global Alzheimer's expert increases scientific expertise
- Nomination Committee represents ~57% shares and ~83% votes
Negative
- Board turnover: one incumbent (Pär Gellerfors) declined re-election
- Independence note: Linda Nilsson not independent to major shareholders
News Market Reaction – BIOA
In the Mar 27 session, BIOA declined 0.62%, reflecting a mild negative market reaction. Argus tracked a peak move of +10.8% during that session. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
The Nomination Committee proposes that the board shall consist of eight members, without deputies.
The Nomination Committee proposes that Eugen Steiner, Cecilia Edström, Anna-Lena Engwall, Lars Lannfelt, Lotta Ljungqvist and Mikael Smedeby be re-elected as board members and that Philip Scheltens and Linda Nilsson be elected as new board members, each for a term of office until the end of the next annual general meeting. Furthermore, the Nomination Committee proposes that Eugen Steiner be re-elected as chairperson.
Board member Pär Gellerfors has declined re-election. The Nomination Committee proposes that his daughter, Linda Nilsson, takes a seat on the board as representative of the Gellerfors family's holding company, Ackelsta AB.
Philip Scheltens is one of the leading international experts in the research, diagnosis and treatment of Alzheimer's disease. Prof. dr. Philip Scheltens studied at the VU University
Linda Nilsson has over 20 years of global experience from the international fashion company H&M. She currently holds the position as Head of Product Operations & Development, where she leads approximately 400 employees and is responsible for strategy, governance, and delivery across both product and production. Previously, Linda was Global Managing Director for Womenswear, with full P&L responsibility for a business area generating
Information on all proposed board members for BioArctic, the Nomination Committee's rationale regarding the proposal for the election of board members and the Nomination Committee's complete proposals to the annual general meeting will be available on the company's website, www.bioarctic.com, in connection with the issuance of the notice to attend the annual general meeting 2026, which is expected to be published on April 21, 2026.
The Nomination Committee has been appointed according to the principles adopted by the Annual General Meeting 2024 and consists of Jannis Kitsakis (chairperson), appointed by the Fourth Swedish National Pension Fund (Swedish: Fjärde AP-fonden), Margareta Öhrvall, appointed by Demban AB and Claes Andersson, appointed by Ackelsta AB. The composition of the Nomination Committee was published on October 20, 2023, and has been made available on the company's website. The members of the Nomination Committee have been appointed by shareholders who together represent approximately 57 percent of the shares and around 83 percent of the votes in the company. The chairperson of the board has been adjunct at the Nomination Committee's meetings.
The Nomination Committee of BioArctic AB (publ)
The information was released for public disclosure, through the agency of the contact persons below, on March 27, 2026, at 08:00 a.m. CET.
For further information, please contact:
Jannis Kitsakis, chairperson of the Nomination Committee, telephone +46 (0)70 603 80 23
Oskar Bosson, VP Communications and Investor Relations
E-mail: oskar.bosson@bioarctic.com
Tel: +46 704 10 71 80
About BioArctic AB
BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company invented Leqembi® (lecanemab) – the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with BioArctic's partner Eisai, who are responsible for regulatory interactions and commercialization globally. In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson's disease and ALS as well as additional projects against Alzheimer's disease. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which has the potential to actively transport antibodies across the blood-brain barrier to enhance the efficacy of the treatment. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For further information, please visit www.bioarctic.com.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
The Nomination Committee's proposal for the election of Board members and Chairperson of the Board in BioArctic AB |
View original content:https://www.prnewswire.com/news-releases/the-nomination-committees-proposal-for-the-election-of-board-members-and-chairperson-of-the-board-in-bioarctic-ab-302727129.html
SOURCE BioArctic